$158.71
0.51% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock price

$158.71
-22.98 12.65% 1M
-59.10 27.13% 6M
-100.06 38.67% YTD
-70.08 30.63% 1Y
-91.42 36.55% 3Y
-143.90 47.55% 5Y
-122.59 43.58% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.81 0.51%
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Key metrics

Market capitalization $23.13b
Enterprise Value $28.08b
P/E (TTM) P/E ratio 14.34
EV/FCF (TTM) EV/FCF 14.42
EV/Sales (TTM) EV/Sales 3.04
P/S ratio (TTM) P/S ratio 2.51
P/B ratio (TTM) P/B ratio 1.41
Revenue growth (TTM) Revenue growth -3.98%
Revenue (TTM) Revenue $9.23b
EBIT (operating result TTM) EBIT $2.12b
Free Cash Flow (TTM) Free Cash Flow $1.95b
Cash position $1.70b
EPS (TTM) EPS $11.07
P/E forward 12.87
P/S forward 2.40
EV/Sales forward 2.91
Short interest 2.42%
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Analyst Opinions

38 Analysts have issued a Biogen forecast:

23x Buy
61%
15x Hold
39%

Analyst Opinions

38 Analysts have issued a Biogen forecast:

Buy
61%
Hold
39%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
9,229 9,229
4% 4%
100%
- Direct Costs 2,975 2,975
3% 3%
32%
6,254 6,254
4% 4%
68%
- Selling and Administrative Expenses 1,703 1,703
14% 14%
18%
- Research and Development Expense 1,803 1,803
19% 19%
20%
2,748 2,748
19% 19%
30%
- Depreciation and Amortization 629 629
6% 6%
7%
EBIT (Operating Income) EBIT 2,119 2,119
23% 23%
23%
Net Profit 1,615 1,615
10% 10%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
GlobeNewsWire
7 days ago
BRUSSELS, Belgium and CAMBRIDGE, Mass., Nov. 19, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe system...
Neutral
GlobeNewsWire
8 days ago
INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has approved OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea1,2 (aflibercept), developed and registered by Samsung Bioepis.
Positive
Barrons
12 days ago
It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,570
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today